Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.

Research output: Contribution to journalArticlepeer-review

11 Citations (SciVal)


PD (Parkinson's disease) is characterized by some typical motor features that are caused by striatal dopamine depletion and respond well to dopamine-replacement therapy with L-dopa. Unfortunately, the majority of PD patients treated with L-dopa develop abnormal involuntary movements (dyskinesias) within a few years. The mechanisms underlying the development of LIDs (L-dopa-induced dyskinesias) involve, on one hand, a presynaptic dysregulation of dopamine release and clearance and, on the other hand, an abnormal postsynaptic response to dopamine in the brain. There is a large amount of evidence that these dopamine-dependent mechanisms are modulated by glutamatergic pathways and glutamate receptors. The present article summarizes the pathophysiological role of glutamatergic pathways in LID and reviews pre-clinical and clinical results obtained using pharmacological modulators of different classes and subtypes of glutamate receptors to treat parkinsonian dyskinesias.
Original languageEnglish
Pages (from-to)600-604
JournalBiochemical Society Transactions
Issue number2
Publication statusPublished - 2014

Subject classification (UKÄ)

  • Biochemistry and Molecular Biology


Dive into the research topics of 'Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.'. Together they form a unique fingerprint.

Cite this